Development of savolitinib resistance through a MET mutation after an initial clinical response and subsequent sensitivity of the tumor to a structurally distinct MET TKI strongly suggest that the tumor retained dependence on MET signaling throughout the course of patient therapy (14). Here, MET is linked to neoplasm.